New Delhi, Nov 20: A new daily pill has shown promising results in treating advanced pancreatic cancer, with tumours becoming undetectable in some patients, in what experts have described as the biggest breakthrough in the treatment of the disease in decades, according to a BBC report. The drug, daraxonrasib, was tested alongside chemotherapy in an early-stage clinical trial involving 61 patients whose pancreatic cancer had spread to other parts of the body, BBC reported.
The trial found that tumours stopped growing in 90 per cent of patients, while just over 60 per cent experienced a reduction in tumour size or complete disappearance. In around eight per cent of patients, or one in 12, cancer became undetectable on scans.
Cancer Research UK described the findings as “the biggest leap forward in decades” for pancreatic cancer patients.
Dr Sam Godfrey of the charity said the drug had found a way of targeting cancer mechanisms previously considered difficult to treat.
However, doctors cautioned that the findings were preliminary and the treatment should not be considered a cure. Longer studies are needed to establish whether the drug can keep cancer under control and improve overall survival. Daraxonrasib belongs to a class of medicines known as KRAS inhibitors. It works by targeting mutations that drive tumour growth and are found in most pancreatic cancers.
Dr Wungki Park of Memorial Sloan Kettering Cancer Center in the US said the results were encouraging, with deeper tumour responses and a near doubling in the duration of disease control, which could eventually translate into longer survival.
Pancreatic cancer is among the deadliest forms of cancer and is particularly difficult to treat, with patients diagnosed at an advanced stage often surviving only months. Researchers hope the new treatment could offer patients more time and potentially open avenues for treating other cancers with similar mutations.
